XENON PHARMACEUTICALS INC.: 10-Q filed 2025-11-03
What XENON PHARMACEUTICALS INC. reported in its quarterly report filed 2025-11-03 (fiscal Q3 2025): 35 published measures, 107 facts as tagged in accession 0001193125-25-262646.
This filing
- Form
- 10-Q (quarterly report)
- Filed
- 2025-11-03
- Fiscal period
- fiscal Q3 2025
- Accession
- 0001193125-25-262646 on SEC EDGAR
Values are as tagged in this filing. A later filing can restate them; each measure links to its history page, which shows the latest-filed value per period. All XENON PHARMACEUTICALS INC. filings.
Reported measures
Total assets
Resources recognized on the balance sheet. Book assets are not the market value of the business.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2025-09-30 | 607,836,000 | USD | |
| At 2024-12-31 | 798,139,000 | USD |
Total liabilities
Recognized obligations at the reporting date. The definition and scope differ from interest-bearing debt.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2025-09-30 | 48,325,000 | USD | |
| At 2024-12-31 | 43,236,000 | USD |
Stockholders equity
The reported residual interest after liabilities. It is an accounting amount, not market capitalization.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2025-09-30 | 559,511,000 | USD | |
| At 2025-06-30 | 633,978,000 | USD | |
| At 2025-03-31 | 703,957,000 | USD | |
| At 2024-12-31 | 754,903,000 | USD | |
| At 2024-09-30 | 797,807,000 | USD | |
| At 2024-06-30 | 844,047,000 | USD | |
| At 2024-03-31 | 887,698,000 | USD | |
| At 2023-12-31 | 927,921,000 | USD |
Cash and cash equivalents
Cash and qualifying short-term liquid investments under the filer’s accounting policy. Restricted cash and longer-term investments may be reported separately.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2025-09-30 | 104,514,000 | USD | |
| At 2024-12-31 | 142,712,000 | USD |
Net income or loss
Reported profit or loss for the period. Check the filing for attribution, exceptional items and discontinued operations before comparing companies.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2025-07-01 to 2025-09-30 | -90,896,000 | USD | 92 |
| 2025-01-01 to 2025-09-30 | -240,649,000 | USD | 273 |
| 2025-04-01 to 2025-06-30 | -84,706,000 | USD | 91 |
| 2025-01-01 to 2025-03-31 | -65,047,000 | USD | 90 |
| 2024-07-01 to 2024-09-30 | -62,790,000 | USD | 92 |
| 2024-01-01 to 2024-09-30 | -168,645,000 | USD | 274 |
| 2024-04-01 to 2024-06-30 | -57,924,000 | USD | 91 |
| 2024-01-01 to 2024-03-31 | -47,931,000 | USD | 91 |
Operating cash flow
Cash generated or used by operating activities. Working-capital timing can make this differ substantially from reported income.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2025-01-01 to 2025-09-30 | -197,637,000 | USD | 273 |
| 2024-01-01 to 2024-09-30 | -127,004,000 | USD | 274 |
Capital expenditure payments
Cash payments to acquire property, plant and equipment. This taxonomy concept does not capture every form of investment or acquisition.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2025-01-01 to 2025-09-30 | 481,000 | USD | 273 |
| 2024-01-01 to 2024-09-30 | 2,292,000 | USD | 274 |
Financing cash flow
Net cash from financing activities, including borrowing, repayments and transactions with owners. A positive amount does not establish operating profitability.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2025-01-01 to 2025-09-30 | 3,576,000 | USD | 273 |
| 2024-01-01 to 2024-09-30 | 0 | USD | 274 |
Investing cash flow
Net cash from investing activities, including asset purchases, disposals and investment transactions. This differs from capital expenditure payments alone.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2025-01-01 to 2025-09-30 | 155,301,000 | USD | 273 |
| 2024-01-01 to 2024-09-30 | 66,497,000 | USD | 274 |
Retained earnings or deficit
Accumulated undistributed earnings or deficit at the reporting date. This balance is not cash available for distribution.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2025-09-30 | -1,140,119,000 | USD | |
| At 2024-12-31 | -899,470,000 | USD |
Basic weighted-average shares
Time-weighted shares used for basic earnings per share. This denominator differs from shares outstanding at a single reporting date.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2025-07-01 to 2025-09-30 | 79,247,976 | shares | 92 |
| 2025-01-01 to 2025-09-30 | 78,962,975 | shares | 273 |
| 2024-07-01 to 2024-09-30 | 77,926,205 | shares | 92 |
| 2024-01-01 to 2024-09-30 | 77,730,644 | shares | 274 |
Diluted weighted-average shares
Weighted-average shares used for diluted earnings per share. Potential shares are included under the applicable dilution rules, not simply added to outstanding shares.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2025-07-01 to 2025-09-30 | 79,247,976 | shares | 92 |
| 2025-01-01 to 2025-09-30 | 78,962,975 | shares | 273 |
| 2024-07-01 to 2024-09-30 | 77,926,205 | shares | 92 |
| 2024-01-01 to 2024-09-30 | 77,730,644 | shares | 274 |
Basic earnings per share
Reported earnings or loss per basic common share or unit. Inspect attribution, share classes and restatements before comparing periods. This is not a market return.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2025-07-01 to 2025-09-30 | -1.15 | USD/shares | 92 |
| 2025-01-01 to 2025-09-30 | -3.05 | USD/shares | 273 |
| 2024-07-01 to 2024-09-30 | -0.81 | USD/shares | 92 |
| 2024-01-01 to 2024-09-30 | -2.17 | USD/shares | 274 |
Diluted earnings per share
Reported earnings or loss per share under dilution rules. Antidilutive instruments may be excluded. A diluted value can equal the basic value without implying no potential dilution.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2025-07-01 to 2025-09-30 | -1.15 | USD/shares | 92 |
| 2025-01-01 to 2025-09-30 | -3.05 | USD/shares | 273 |
| 2024-07-01 to 2024-09-30 | -0.81 | USD/shares | 92 |
| 2024-01-01 to 2024-09-30 | -2.17 | USD/shares | 274 |
Income tax expense or benefit
Current and deferred income tax expense or benefit for continuing operations. This accounting expense differs from cash taxes paid.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2025-07-01 to 2025-09-30 | 677,000 | USD | 92 |
| 2025-01-01 to 2025-09-30 | 478,000 | USD | 273 |
| 2024-07-01 to 2024-09-30 | -320,000 | USD | 92 |
| 2024-01-01 to 2024-09-30 | -241,000 | USD | 274 |
Net property, plant and equipment
Carrying amount of property, plant and equipment after accumulated depreciation, depletion and amortization. It is not replacement cost or market value.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2025-09-30 | 8,887,000 | USD | |
| At 2024-12-31 | 10,278,000 | USD |
Share-based compensation expense
Reported noncash expense for share-based payment arrangements. Noncash treatment does not mean the awards have no economic cost to shareholders.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2025-07-01 to 2025-09-30 | 13,705,000 | USD | 92 |
| 2025-01-01 to 2025-09-30 | 39,592,000 | USD | 273 |
| 2024-07-01 to 2024-09-30 | 13,002,000 | USD | 92 |
| 2024-01-01 to 2024-09-30 | 37,118,000 | USD | 274 |
Operating income or loss
Operating revenue less operating expenses for the reporting period. It excludes items outside the reported operating result and is not free cash flow.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2025-07-01 to 2025-09-30 | -96,336,000 | USD | 92 |
| 2025-01-01 to 2025-09-30 | -263,303,000 | USD | 273 |
| 2024-07-01 to 2024-09-30 | -73,676,000 | USD | 92 |
| 2024-01-01 to 2024-09-30 | -201,821,000 | USD | 274 |
Current assets
Assets classified as current under the normal operating cycle or one-year boundary. Not all current assets can be converted immediately into cash.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2025-09-30 | 480,137,000 | USD | |
| At 2024-12-31 | 635,264,000 | USD |
Current liabilities
Obligations classified as current under the operating-cycle or one-year boundary. The balance includes more than short-term borrowing.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2025-09-30 | 38,335,000 | USD | |
| At 2024-12-31 | 35,590,000 | USD |
Operating expenses
Recurring operating costs under this accounting concept, generally excluding production costs included in cost of sales. Check filing presentation before combining expense subtotals.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2025-07-01 to 2025-09-30 | 96,336,000 | USD | 92 |
| 2025-01-01 to 2025-09-30 | 270,803,000 | USD | 273 |
| 2024-07-01 to 2024-09-30 | 73,676,000 | USD | 92 |
| 2024-01-01 to 2024-09-30 | 201,821,000 | USD | 274 |
Research and development expense
Research and development costs recognized as expense. Capitalization policies and acquired projects can make this differ from total cash invested in development.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2025-07-01 to 2025-09-30 | 77,054,000 | USD | 92 |
| 2025-01-01 to 2025-09-30 | 213,239,000 | USD | 273 |
| 2024-07-01 to 2024-09-30 | 56,970,000 | USD | 92 |
| 2024-01-01 to 2024-09-30 | 150,922,000 | USD | 274 |
Common shares outstanding
Common shares outstanding at the reporting date. This point-in-time count differs from the weighted-average shares used for earnings per share and can exclude other share classes.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2025-09-30 | 77,120,168 | shares | |
| At 2024-12-31 | 76,416,086 | shares |
Accumulated other comprehensive income or loss
Cumulative other comprehensive items after tax, such as translation and unrealized hedging or securities effects. These amounts have not passed through net income.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2025-09-30 | 477,000 | USD | |
| At 2024-12-31 | -1,612,000 | USD |
Operating lease right-of-use asset
Carrying amount of the right to use leased assets under operating leases. It reflects discounted remaining payments, not the value of the underlying property.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2025-09-30 | 6,960,000 | USD | |
| At 2024-12-31 | 7,939,000 | USD |
Operating lease liability
Present value of remaining operating lease payments. Discount-rate choices and lease terms affect the amount; it is not the sum of undiscounted future rent.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2025-09-30 | 8,327,000 | USD |
Other noncurrent liabilities
Noncurrent liabilities the filer does not present separately. The composition differs by filer and is described only in the filing.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2025-09-30 | 3,158,000 | USD | |
| At 2024-12-31 | 0 | USD |
Prepaid expenses and other current assets
Prepayments and other current assets grouped under this concept. The balance is not cash and its composition differs by filer.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2025-09-30 | 17,057,000 | USD | |
| At 2024-12-31 | 6,890,000 | USD |
Pre-tax income or loss from continuing operations
Income or loss from continuing operations before income taxes and noncontrolling interests. It excludes discontinued operations and is not net income.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2025-07-01 to 2025-09-30 | -90,219,000 | USD | 92 |
| 2025-01-01 to 2025-09-30 | -240,171,000 | USD | 273 |
| 2024-07-01 to 2024-09-30 | -63,110,000 | USD | 92 |
| 2024-01-01 to 2024-09-30 | -168,886,000 | USD | 274 |
Profit or loss including noncontrolling interests
Net income or loss including the portion attributable to noncontrolling interests. It can differ from the net income attributable to the parent that per-share figures use.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2025-01-01 to 2025-09-30 | -240,649,000 | USD | 273 |
| 2024-01-01 to 2024-09-30 | -168,645,000 | USD | 274 |
Comprehensive income or loss
Net income plus other comprehensive income after tax. It includes unrealized items that net income excludes and is not a cash measure.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2025-07-01 to 2025-09-30 | -90,532,000 | USD | 92 |
| 2025-01-01 to 2025-09-30 | -238,560,000 | USD | 273 |
| 2024-07-01 to 2024-09-30 | -59,242,000 | USD | 92 |
| 2024-01-01 to 2024-09-30 | -167,232,000 | USD | 274 |
General and administrative expense
General and administrative costs reported under this concept, separate from selling expense. Filers group overhead differently, so compare presentation before comparing companies.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2025-07-01 to 2025-09-30 | 19,282,000 | USD | 92 |
| 2025-01-01 to 2025-09-30 | 57,564,000 | USD | 273 |
| 2024-07-01 to 2024-09-30 | 16,706,000 | USD | 92 |
| 2024-01-01 to 2024-09-30 | 50,899,000 | USD | 274 |
Nonoperating income or expense
Total nonoperating income or expense, which can include interest, investment results and other items. A positive value is not operating profit.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2025-07-01 to 2025-09-30 | 6,117,000 | USD | 92 |
| 2025-01-01 to 2025-09-30 | 23,132,000 | USD | 273 |
| 2024-07-01 to 2024-09-30 | 10,566,000 | USD | 92 |
| 2024-01-01 to 2024-09-30 | 32,935,000 | USD | 274 |
Deferred income tax expense or benefit
The deferred portion of income tax expense or benefit, arising from timing differences. It is not tax paid in the period.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2025-01-01 to 2025-09-30 | -2,084,000 | USD | 273 |
| 2024-01-01 to 2024-09-30 | -252,000 | USD | 274 |
Operating lease payments
Cash paid for operating lease liabilities during the period. It differs from lease expense recognized and excludes variable payments in some presentations.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2025-01-01 to 2025-09-30 | 1,280,000 | USD | 273 |
| 2024-01-01 to 2024-09-30 | 1,245,000 | USD | 274 |
Inspect the source
- Entity
- XENON PHARMACEUTICALS INC. / CIK 0001582313
- Captured
- 2026-09-20T09:22:52.756Z
- SEC response SHA-256
192f372ec04a5f134b187ed4baddde08f5cf5af14daba171e6067f98261efde5
Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON
Every published concept a filing tagged, with the periods it covered, as reported in that filing at capture time. Forms 10-K, 10-K/A, 10-Q, 10-Q/A, 20-F, 20-F/A, 40-F, 40-F/A. A filing page needs at least 8 published concepts. Later filings can restate these values; the company history pages show the latest-filed value per period.
Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.
Use this in research
A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.
These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.
Research methodology · Execution and cost assumptions · Check backtest overfitting
Build with the open-source tools
Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.
- Get an API key and run your first validation
- Connect the MCP server to your coding assistant
- Inspect the ALPHAC engine on GitHub
- Read the MCP server source and integration examples
Read the published dataset with Python
import json
from urllib.request import urlopen
with urlopen("https://canlicapital.com/company-data/0001582313.json") as response:
record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
print(concept["tag"], next(iter(concept["observations"])))